More and more, Dendreon is looking like Trimeris (TRMS), the once high-flying HIV drug company that unraveled because its novel HIV drug was too costly to make and too difficult to sell.
Provenge sales rose 30% to $64 million in the September quarter over June but Dendreon's expenses grew even more, most notable in a horrific 10% gross margin.
The unexpected rise in Provenge's cost of goods coupled with management's admission that sales of the prostate cancer therapy will slow down for the rest of the year sent Dendreon shares tumbling 23% to $8.10 Thursday's pre-market session.Dendreon will not survive long with a 10% gross margin, or as cancer consultant Michael Becker of MD Becker Partners quipped on Twitter: "Dear Dendreon -- 'We lose a dollar on every sale but make it up on volume' is not a viable business model." Provenge is a real scientific breakthrough -- a first-of-its-kind cancer "vaccine" that trains a patient's immune system to seek out and destroy tumor cells. But the high fixed costs and complex logistics required to manufacture and deliver the personalized therapy is proving to be Dendreon's undoing. The company still insists it can reach cash-flow break even at $500 million in U.S. Provenge sales, but when that happens and whether Dendreon can ever achieve profit margins investors expect from drug makers isn't clear. The poor third-quarter financial picture doesn't inspire confidence. Stepping back from the numbers, perhaps Dendreon's larger problem is that Provenge is already being eclipsed by other more promising prostate cancer therapies. When Provenge was being developed, drugs that extended the lives of patients with advanced prostate cancer were rare. Now, doctors have a growing menu of life-extending drugs to choose from, including Johnson & Johnson's (JNJ) Zytiga and Sanofi's (SNY) Jevtana. Looking ahead, the buzz in prostate cancer is about Algeta's Alpharadin, Medivation's (MDVN) MDV3100 and Exelixis' (EXEL) cabozantinib, all still experimental but which also have the potential to dramatically extend prostate cancer survival.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV